skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Biosimilars – commercial best practices in the age of sustainability

See how biosimilars are the leading growth engine of global medicines spending:

  • Revenues from biologics increased by 70% from 2011 to 2016
  • Biologics account for 20-22% of total pharmaceutical spending
  • IQVIA estimates US biologics spending will reach $320bn by 2023
Biosimilars-whitepaper-cover-image

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: